Shots:
- Pharmapark will hold exclusive distribution, and marketing rights & filing for BAT2306 (Secukinumab bsm) which has finished the P-I & P-III study globally and plans to submit applications for approval to the NMPA, EMA & FDA.
- Under the terms of the agreement, BAT2306 will be developed & supplied by Bio-Thera at its Guangzhou, China facility, and Pharmapark will be responsible for the regulatory & commercial activities across Russia and CIS countries
- This is a third expansion of the existing agreement between the two companies which includes BAT2506 (Biosimilar, Golimumab) also includes BAT2206 (Biosimilar, Ustekinumab)
Ref: Bio-Thera Solutions | Image: Bio-Thera Solutions | Press Release
Related News:- Celltrion’s SteQeyma (Biosimilar, Stelara) Receives the EC’s Approval to Treat Various Chronic Inflammatory Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
